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Abstract  
Background The aim of this randomised, placebo-controlled, double-blind, multicentre trial 
was to investigate the efficacy and safety of apomorphine infusion over placebo in patients 
with Parkinson´s disease (PD) and persistent motor fluctuations despite optimised 
oral/transdermal treatment. 
Methods Subjects were enrolled at 23 European centres and had a diagnosis of PD of >3 
years’ duration with motor fluctuations not adequately controlled on medical treatment. 
Subjects gave written informed consent; local ethics committees approved the study. Patients 
were randomised in a 1:1 ratio stratified by site to receive apomorphine or placebo saline 
infusion during waking hours (16±2 hours) at 3–8 mg/hour for 12 weeks. Based on individual 
efficacy and tolerability, the flow rate of the study drug and oral medication were adjusted 
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during 4 weeks, followed by an 8-week maintenance period. The primary endpoint was the 
absolute change in daily ‘off’ time based on patient diaries (intention-to-treat analysis). 
Findings 107 patients were randomised and 106 included in the full-analysis set (one did not 
provide any post-baseline efficacy data). Apomorphine infusion (n=53; mean [±SD] final 
dose: 4·68±1·50 mg/hour) provided statistically significantly greater reduction in ‘off’ time 
compared with placebo (n=53); difference between treatment groups of -1·89 hours (95% CI: 
-3·16, -0·62; p=0·0025). Apomorphine was well tolerated without unexpected safety signals.  
Interpretation The TOLEDO study provides the level-1 evidence previously lacking. 
Apomorphine infusion resulted in statistically significant and clinically meaningful ‘off’ time 
reduction without increasing dyskinesias in PD patients with persistent motor fluctuations 
despite optimised oral/transdermal therapy. 
 
Funding 
Britannia Pharmaceuticals Limited funded the study, registered at ClinicalTrials.gov 
(NCT02006121). 
 
Keywords 
Parkinson's disease; apomorphine subcutaneous infusion; motor fluctuations; off-time; 
dyskinesia. 
 
Introduction  
Parkinson’s disease (PD) is characterised by neurodegeneration of the substantia nigra with 
progressive striatal dopamine deficiency and motor symptoms.1 
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Dopamine replacement therapy is efficacious but in most patients levodopa eventually leads 
to motor fluctuations as the disease progresses. These are typically managed by redistributing 
levodopa and adding monoamine oxidase type B (MAO-B) inhibitors, catechol-O-methyl 
transferase (COMT) inhibitors, and oral/transdermal dopamine agonists.2 Over time, motor 
fluctuations usually worsen, leading to significant periods of immobility and non-motor 
symptoms, and attempts to control fluctuations with oral medication may lead to disabling 
dyskinesia. Persistent motor complications may be managed by deep brain stimulation (DBS) 
or continuous dopaminergic drug delivery, using the subcutaneous infusion of the dopamine 
agonist apomorphine or the intestinal infusion of levodopa/carbidopa gel (LCIG). High-level 
evidence exists for the efficacy of DBS and LCIG, but both treatments are invasive and carry 
a specific spectrum of risks.3  
 
Apomorphine is a potent dopamine receptor agonist with affinity for all dopamine receptor 
subtypes.4 It was first licensed in the United Kingdom (UK) in 1993 for PD based on an 
open-label, comparative study5 which demonstrated equivalent antiparkinsonian efficacy to 
levodopa, and it remains the only medication with the same symptomatic efficacy as 
levodopa. Subcutaneous apomorphine infusion is currently licensed for severe motor 
fluctuations and reimbursed by several healthcare systems across the world. Numerous short- 
and long-term uncontrolled studies have demonstrated its efficacy in reducing ‘off’ time (up 
to 80%), and most – but not all – also showed an improvement in dyskinesias and 
concomitant reductions in oral levodopa doses.4,6,7 Despite its long-standing clinical use, 
apomorphine infusion has never been tested in a randomised, controlled trial (RCT), which is 
a significant weakness in the formal evidence base for this therapeutic modality.  
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We present here results of the 12-week, double-blind phase of the TOLEDO study, the first 
prospective, randomised, placebo-controlled trial to investigate the efficacy and safety of 
apomorphine subcutaneous infusion in PD patients.  
 
Methods 
Study design 
The TOLEDO study was a prospective, multicentre, Phase III study with the primary 
objective of demonstrating the efficacy of apomorphine subcutaneous infusion compared 
with placebo in levodopa-treated PD patients with persistent motor fluctuations despite 
optimised oral/transdermal medication. A secondary objective was to investigate the safety 
and tolerability of apomorphine infusion. The trial included a 12-week, parallel-group, 
double-blind, placebo-controlled phase (Figure 1) followed by a 52-week open-label phase. 
TOLEDO was performed in accordance with the International Conference of Harmonization 
guidelines on Good Clinical Practice E6 and the Declaration of Helsinki 2013.8 Prior to the 
start of the study, the study protocol, patient information sheet, and informed consent were 
approved by the independent ethics committees and the competent regulatory authorities in 
accordance with local legal requirements in each participating country.  
 
Subjects 
Participants were enrolled at 23 university and general hospitals specialised in the treatment 
of PD across Austria, Denmark, France, Germany, Spain, the Netherlands and the UK. 
Subjects were male or female patients aged ≥30 years with a diagnosis of PD of >3 years’ 
duration, as defined by the Queen Square Brain Bank criteria (with the exception of affected 
relatives allowed),9 and levodopa-related motor fluctuations not adequately controlled on 
medical treatment, which had to include ≥4 daily intakes of oral levodopa and to be judged to 
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be optimal by the investigator. Patients’ Hoehn & Yahr stage had to be ≤3 in the ‘on’ state 
and 2–5 in the ‘off’ state. They were required to have been on stable doses of oral medication 
for ≥4 weeks prior to enrolment, needed to be able to differentiate between their subjective 
‘on’ and ‘off’ state and between ‘on’ with troublesome and non-troublesome dyskinesia and 
without dyskinesia, and to document those states in the diary. Eligible patients had to have an 
average of ≥3 hours of ‘off’ time per day for 2 days based on diaries at screening and 
baseline, with no day with <2 hours ‘off’ time recorded.10 All oral or transdermal 
antiparkinsonian drugs available in the participating countries were permitted, except 
budipine.  
 
Exclusion criteria included secondary and atypical parkinsonian syndromes, previous 
neurosurgical treatment for PD, previous use of apomorphine infusion, and treatment during 
the 28 days prior to enrolment with apomorphine injections, intrajejunal levodopa or any 
neuroleptic drug treatment. Patients were also excluded if they had severe freezing leading to 
falls during ‘on’, clinically relevant postural instability during ‘on’, or symptomatic, 
clinically relevant uncontrolled orthostatic hypotension, prolonged QT duration, clinically 
relevant cognitive decline (defined as Mini Mental State Examination score 24 or according 
to DSM IV-criteria) or psychosis judged to be at least moderate during the previous year or 
currently. Very mild visual hallucinations (illusions of passage or presence), with fully 
retained insight, were permitted. All patients provided written informed consent prior to 
enrolment. 
 
Randomisation and masking 
Eligible patients were randomised in a 1:1 ratio within a block size of 4 stratified by site to 
either apomorphine or placebo subcutaneous infusion, according to a central, computer-
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generated randomisation code generated by the Biometric Department of Advanced Medical 
Services GmBH using SAS software. The Electronic Data Capture (EDC) system used for 
study was Clincase, provided by Quadratek Data Solutions Ltd. All study participants and 
investigators were masked to group assignment. Although success of masking was not 
formally assessed, every effort was made to maintain blinding throughout the study. There 
were two separate teams of investigators at each centre: Team 1 reviewed laboratory results, 
safety and tolerability, collected diary data and adjusted the dose of study drug and 
concomitant medication. Team 2 assessed Movement Disorder Society Unified Parkinson's 
Disease Rating Scale (MDS-UPDRS) scores 11 and Patient Global Impression of Change 
(PGIC).12 Neither team had access to data recorded or collected by the other team. Study 
participants and their carers were instructed not to discuss their medication or any observed 
effects or possible adverse events (AEs) with Team 2 investigators. All investigators were 
instructed not to communicate their own perception of possible treatment assignment to the 
other team of investigators, patients or carers.  
 
Dosing 
Apomorphine subcutaneous infusion was provided in 10 ml glass pre-filled syringes 
(manufactured by Catalent Pharma Solutions, Brussels, Belgium) and delivered as a 5 mg/ml 
solution for infusion using a Canè CRONO APO-Go infusion pump. A placebo saline 
infusion produced by the same manufacturer and identical to apomorphine in appearance, 
weight and packaging was provided in identical pre-filled syringes and administered using 
the same pump system.  
 
The target dose of apomorphine was each patient’s individual optimised dose at hourly flow 
rates of 3–8 mg, administered for approximately 16 hours of their waking day. Infusion times 
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of 14–18 hours were permissible and any shorter duration (minimum 12 hours) required an 
explanation by the investigator. Initiation of treatment was undertaken during a hospital stay 
of 5–10 days, where patients/carers received infusion-system training. Day-case 
hospitalisation was permitted in those centres where outpatient titration was already standard 
practice. Antiemetic pre-medication was administered according to local standards and the 
investigator’s judgement. For domperidone, the recommended dose was 10 mg ≤3 times/day 
starting three days before the infusion.13 On Day 1, patients received a starting dose of the 
study drug at a flow rate of 1 mg/hour. During the in-patient/day case dose-adjustment 
period, the flow rate could be adjusted daily by 0·5–1·0 mg/hour, and weekly after that up to 
the end of Week 4, until the maximum of 8 mg/hour or the highest tolerated dose was 
reached, whichever occurred first. Patients were required to be discharged on ≥3 mg/hour. 
 
Any reductions in concomitant PD medications were driven by the emergence of possible 
dopaminergic effects, in particular dyskinesias, nausea, orthostatic hypotension, or sleepiness. 
If applicable, oral medication was reduced in a hierarchical manner (Figure 1), with the aim 
of reducing and discontinuing oral/transdermal dopamine agonists first, followed by MAO-B 
inhibitors. For levodopa or combined levodopa/COMT, doses were to be reduced first, 
followed by an increase in the intervals between intakes. COMT inhibitors could be 
discontinued. Amantadine and anticholinergics were left unchanged. The titration period was 
followed by an 8-week maintenance period on stable doses. Use of the bolus function of the 
pump was not permitted and levodopa rescue doses for ‘off’ periods were limited to 300 
mg/day during the titration phase and 200 mg/day during the maintenance phase. In addition, 
patients developing nocturnal ‘off’-periods following discontinuation of controlled-release 
dopamine agonists could be re-started on that agonist up to the original dose at bed-time. 
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After completing the 12-week double-blind phase, or in the case of withdrawal due to lack of 
efficacy, patients were offered treatment with apomorphine infusion in the 52-week open-
label phase of the trial. 
 
Visits and evaluations 
During the double-blind phase, visits were performed at baseline and at Weeks 2, 3, 4, 6, 8, 
10, and 12. Patients received training in diary completion, including daily infusion time 
records. For two days prior to baseline, every day during the in-patient /day case stay, and for 
two days prior to each visit at Weeks 2, 3, 4, 6 and 12, patients completed the 24-hour home 
diary assessment of motor status at 30-minute intervals, recording periods when they were 
‘on’ without dyskinesia, without troublesome dyskinesia or with troublesome dyskinesia, 
‘off’ and sleeping. Additional evaluations at each visit included vital signs and safety 
assessments. Clinical laboratory variables were performed at baseline, at the end of the 
hospitalisation period, and then monthly. 
 
Outcome measures and statistical analysis 
The primary efficacy endpoint was the absolute change in time spent ‘off’ (derived from 
patient diaries) from baseline to the visit at Week 12. Secondary efficacy endpoints were 
response to therapy, defined as an ‘off’ time reduction of ≥2 hours from baseline, PGIC, 
absolute change in time spent ‘on’ without troublesome dyskinesia, change in oral levodopa 
dose and levodopa-equivalent dose (LED),14 change in MDS-UPDRS Part III (motor 
examination) scores during ‘on’ periods, and change in quality of life (QoL) assessed using 
the 8-item Parkinson’s Disease Questionnaire (PDQ-8).15 Safety assessments included 
evaluation of AEs and local tolerability, clinical and laboratory parameters, 
electrocardiograms, Questionnaire for Impulsive–Compulsive Disorders in PD (QUIP; long 
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version),16 Epworth Sleepiness Scale (ESS),17 and the Columbia Suicide Severity Rating 
Scale (C-SSRS).18  
 
Sample size was calculated based on previous experience and a review of published data, and 
assumed an ‘off’ time baseline value of 6·5 hours would be reduced to 3·5 hours with 
apomorphine and to 5 hours with placebo.19,20 Thirty-four patients in each arm would provide 
90% power with 5% two-sided significance to detect a treatment effect of 1·5 hours assuming 
a standard deviation (SD) of 1·75 and 2·5 hours ‘off’ time reduction for the apomorphine and 
placebo arms, respectively. Randomisation of 102 patients provided an additional 5% to 
allow for a non-parametric statistical test and an assumption that 30% would not be evaluable 
for the primary endpoint. 
 
All randomised patients who received at least one dose of trial medication and for whom any 
post-baseline efficacy assessment was available were included in the analysis of baseline and 
efficacy data (full analysis set; FAS) using the intention-to-treat principle. Missing data for 
the primary endpoint were imputed using a last-observation-carried-forward (LOCF) 
approach. Sensitivity analyses were conducted using only post-titration values to perform 
LOCF, fitting a mixed model for repeated measurements (MMRM) assuming missing data 
were missing at random and multiple imputation (MI). Descriptive safety data is based on the 
safety dataset which comprised all patients who received at least one dose of trial medication 
and were analysed ‘as treated’.  
 
Apomorphine has been licensed and clinically used in all the study countries for many years. 
With the exception of mandated titration and prohibited use of bolus dosing, the trial design 
closely resembled routine clinical use. The study drug was identical to commercial product. 
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This low-risk study design negated the need for a Data Safety Board (DSB) but the trial was 
overseen by a steering committee of specialist PD neurologists with extensive apomorphine 
infusion experience. A planned blinded interim analysis confirmed the assumptions of sample 
size calculation but could not rule out potentially harmful worsening of symptoms in placebo 
treated patients due to increased ‘off’ time. The sponsor subsequently chartered Clintrex LLC 
(Independent Data Review Committee [IDRC]) who reviewed data for 76 randomised 
patients and found no undue risk and recommended continuation of the study as planned. 
Direct data transfer between the unblinded CRO staff and the IDRC meant no study staff 
were exposed to unblinded data. 
 
Except for the model-based sensitivity analyses mentioned below, the Wilcoxon rank test was 
used to compare the treatment groups for continuous and ordinal variables. Fisher’s exact test 
was used to compare the treatment groups for nominal categorical variables. For the Model-
based sensitivity analyses, MMRM used difference in least squares mean and MI used 
ANCOVA. The statistical package used was SAS 9.4. 
 
Data sharing 
The TOLEDO study data will be available to investigators whose proposed use of the data 
has been approved by an independent review committee. Individual participant data that 
underlie the results reported in this article will be shared (text, tables, figures, and 
appendices), after de-identification, along with the study protocol, statistical analysis plan and 
analytic code. These data will be available 3 months following the article’s publication and 
will be available for 36 months from publication. Requests and proposals should be directed 
to CTD@britannia-pharm.co.uk; to gain access, data requestors will need to sign a data 
access agreement. 
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Role of sponsor 
The study was registered at ClinicalTrials.gov (NCT02006121). The trial protocol is 
available at: www.britannia-pharm.co.uk then click on the ‘Research’ tab. Britannia 
Pharmaceuticals Limited funded the study, participated in the study design, provided funding 
for editorial and formatting assistance (under corresponding author direction), and was 
responsible for data collection, monitoring and statistical analysis. Sponsor authors critically 
reviewed the manuscript and approved the final submission. All authors had full access to all 
data and were responsible for writing the manuscript. The corresponding author had the final 
responsibility for content and the decision to submit for publication. 
 
Results 
Between 3 March 2014 and 1 March 2016, 128 patients were screened for eligibility. One 
hundred and seven of them met the eligibility criteria, signed an approved informed consent, 
were enrolled and randomly assigned to a treatment group (apomorphine=53; placebo=54). 
One hundred and six patients met the protocol definition of ‘evaluable’ with a pre-and post-
infusion efficacy assessments, so that their data contributed to efficacy analyses. One of these 
did not have any post-baseline diary data so did not contribute to the primary endpoint 
analysis using LOCF.  Of those patients, 71 completed all 12 weeks of the study 
(apomorphine=41; placebo=30) (Figure 2) and a further 35 contributed off-time diary data to 
the primary endpoint.  
 
Overall, 36 patients discontinued the double-blind phase before Week 12: 12 in the 
apomorphine group (2 switched early to the open-label phase, 10 discontinued the study) and 
24 in the placebo group (16 switched early to the open-label phase, 8 discontinued the study). 
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The most common reasons for discontinuation were AEs in the apomorphine group 
(n=6;11·3%) and lack of efficacy in the placebo group (n=16; 29·6%).  
 
Baseline characteristics are summarised in Table 1; a breakdown of patients by country of 
origin is shown in Table S1 (Supplementary Material). Demographic variables were balanced 
across the treatment arms, as were anti-PD medications taken at baseline (Supplementary 
Material, Table S2). 
 
The mean (±SD) final dose of study medication was 4·68±1·50 mg/hour (range: 1·5–
8mg/hour) in the apomorphine arm and 5·76±1·79 mg/hour (range: 0–8·0 mg/hour) in the 
placebo arm.  
 
Primary and secondary endpoints 
Compared to subjects randomised to placebo infusions, patients on active apomorphine 
infusions had significantly greater reductions in their time spent ‘off’ as well as in time spent 
‘on’ without troublesome dyskinesia (Table 2, Figure 3a). Significant differences in favour of 
apomorphine were also observed for a percentage of patients with ≥2 hours of ‘off’ time 
reduction, PGIC, and reduction in oral LED. The mean (±SD) change from baseline in ‘off’ 
time at week 12 was -2.47 (3.70) hours and -0.58 (2.80) hours for the apomorphine and 
placebo groups respectively.  The difference in the changes in ‘off’ time between the groups 
from baseline to Week 12 was -1·89 hours (95% CI: -3·16, -0·62; p=0·0025). These results 
were consistent across pre-specified subgroups (gender and age group <65 years and ≥65 
years; Supplementary Material, Figure S1) and the sensitivity analyses (Supplementary 
Material, Figure S2).  
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A significant positive improvement in ‘off’ time with apomorphine infusion was observed at 
Week 1 (treatment difference 1·62 hours) and was sustained over 12 weeks (Figure 3b). For 
absolute change in time spent ‘on’ without troublesome dyskinesia at Week 12, the difference 
between treatment groups was 1·97 hours (95% CI: 0·69, 3·24; p=0·0008) (Table 2). The 
proportion of patients who achieved ≥2 hours of ‘off’ time reduction at Week 12 was 
significantly higher for apomorphine than placebo (62·3% vs 28·8%; p=0·0008).  
 
Post hoc analysis of absolute change in time spent ‘on’ with no dyskinesia, with non-
troublesome dyskinesia and with troublesome dyskinesia are shown in Table S3 
(Supplementary Material). Frequency of patients experiencing ‘on’ time with troublesome 
dyskinesia at baseline is shown in Table S4 (Supplementary Material). 
 
The beneficial effects of apomorphine infusion were reflected in the improved PGIC scores 
(p<0·0001; Figure 4). At Week 12, 70·9% of patients in the apomorphine group stated 
improvement in their general health state compared with 17·6% in the placebo group (Table 
2).  
 
At Week 12, the mean change in oral levodopa dose from baseline showed a trend towards a 
greater reduction in the apomorphine infusion arm, but the difference between treatment 
groups did not reach statistical significance at the 5% level (p=0·0615; Table 2). There was a 
significantly greater reduction in oral LED between baseline and Week 12 in the 
apomorphine group compared with the placebo group (treatment difference [95% CI]: -328·5 
mg [-535·2, -121·7]; p=0·0014; Figure 5 and Table 2). This difference between treatment 
groups was significant at all visits from Week 4. Mean LED at baseline and Week 12 by drug 
category is shown in Table S5 (Supplementary Material). 
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No significant difference at the two-sided 5% level between treatment groups was observed 
at Week 12 in QoL assessed using PDQ-8 or in measures of MDS-UPDRS Part III motor 
scores during ‘on’ periods (Table 2).  
 
A list of exploratory efficacy and safety endpoints is shown in Table S6 (Supplementary 
Material). 
 
Safety and tolerability 
Overall, apomorphine infusion was well tolerated and the frequency and profile of treatment-
related AEs were as predicted from its long-standing clinical use (Table 3); no unexpected 
safety signals were observed. Most events were mild or moderate in intensity and no deaths 
occurred during the study. The overall incidence of AEs was higher in the apomorphine 
group (92·6%) than in the placebo group (56·6%). The most common AEs were skin 
reactions, nausea and somnolence. A greater proportion of patients in the apomorphine group 
(48·1%) experienced AEs that required dose modification compared with the placebo group 
(11·3%). A summary of AEs at Week 12 for the safety set showing Clopper–Pearson exact 
confidence intervals in given in Table S7 (Supplementary Material). 
 
AEs led to study withdrawal in six patients, all randomised to apomorphine. Three patients 
withdrew due to serious AEs (SAEs) (one severe hypotension, one myocardial infarction 
[MI], 1 persistent moderate abnormal haematology test [mild leukopenia and moderate 
anaemia with a lowest haemoglobin level of 9·5 mg, found not to be haemolytic]) and three 
further patients withdrew due to AEs (one visual hallucination, one moderate gait 
disturbance, one mild infusion site erythema, all of which resolved following cessation of the 
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study drug). Except for the MI, all AEs leading to withdrawal were considered at least 
possibly treatment related. No patients from the placebo group withdrew due to AEs.   
 
SAEs occurred in five patients in the apomorphine group: In addition to the three cases that 
led to withdrawal, as described above, one case of severe intermittent confusion (resolved on 
dose reduction) and one severe infusion site cellulitis (resolved). In the placebo arm, two 
SAEs occurred: one severe depression, one colitis.  
 
Neuropsychiatric changes observed in the apomorphine group were one case of mild 
hypersexuality (resolved on study drug dose reduction), two cases of mild punding (one 
resolved and the other did not; in each case the apomorphine dose was not changed), three 
episodes of confusion in a single patient (two mild and one severe, as listed above; all 
resolved on dose reduction), one case of moderate psychosis (resolved without dose change) 
and two cases of hallucinations (one mild which resolved without dose change; one moderate 
which resolved following cessation of the study drug, as listed above). In the placebo group 
there were three reported episodes of mild confusion (two patients) and two cases of mild 
hallucinations (all resolved).  
 
No treatment group differences were observed in ESS scores, which were within the normal 
range for daytime sleepiness, or in C-SSRS scores.  
 
Discussion  
This is the first prospective, double-blind, randomised, placebo-controlled, multicentre study 
of apomorphine subcutaneous infusion in patients with PD and demonstrates that, in 
comparison with placebo, apomorphine subcutaneous infusion provided a significant 
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reduction in ‘off’ time in patients who were experiencing motor fluctuations that were 
persistent despite adjustments in their oral/transdermal medication. Importantly, this 
improvement was not achieved at the expense of worsening dyskinesias.  
 
The treatment effect, or mean difference in ‘off’ time between the apomorphine and placebo 
groups, was almost two hours, both for the reduction in ‘off’ time and the increase in ‘on’ 
time without troublesome dyskinesia. While this effect size is smaller than previously 
reported for uncontrolled studies,4,6,7 inclusion of the placebo response brings the data in line 
with the total reduction in ‘off’ time as reported in open-label studies, and the majority (68%) 
of apomorphine-treated patients achieved more than two hours reduction in ‘off’ time. This 
magnitude of effect exceeds that seen with oral or transdermal medication when tested in 
placebo-controlled, randomised trials,21 and is around double the change in ‘off’ time 
identified as clinically meaningful to patients.22  
 
The clinical relevance of these results was highlighted by the PGIC, where significantly more 
patients in the apomorphine group rated themselves as improved than in the placebo group. 
Apomorphine infusion also allowed for a significant reduction in oral medication, which is 
considered to be the main reason why continuous dopaminergic drug delivery can reduce 
‘off’ time without worsening dyskinesias. This reduction is likely of clinical importance to 
patients with motor complications as it may alleviate the burden of complex oral treatment 
regimens.  
 
Although no precise definition was used for ‘treatment optimisation’ in terms of drug classes 
or sequence of therapy, enrolled patients were required to be receiving oral medication 
considered to be optimal by the investigator. All centres had long-standing experience in the 
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management of complex PD motor complications, including the indication for device-aided 
treatments for persistent motor fluctuations which, by definition, requires all other options to 
have been offered to the patients with insufficient benefit. Patients’ baseline characteristics, 
including antiparkinsonian medication, were similar to those reported in other studies of 
treatments for persistent motor complications. 2,23 In contrast to the TOLEDO study, the 
design of the LCIG study involved discontinuation of COMT inhibitors and slow release 
levodopa preparations before randomisation (for conversion into immediate-release and 
intestinal levodopa) and it allowed treatment optimisation in all participants (due to the 
double-dummy design), resulting in greater levodopa doses at final visit compared to baseline 
in both arms. 
 
The lack of a significant effect on MDS-UPDRS Part III motor scores during ‘on’ periods 
was expected and also supports the fact that eligible patients were receiving optimised oral or 
transdermal treatment at experienced centres.  
 
AE reports and tolerability were in line with those reported in previous observational 
studies,4,6 with most apomorphine-treated patients experiencing at least one AE during the 
study. All six AEs that led to discontinuation occurred in the apomorphine arm and five were 
classified as at least possibly related to treatment. However, none had a sustained negative 
effect, and all were reversed on cessation of treatment. The only reported case of infusion site 
reaction classified as severe resolved without leading to withdrawal. Somnolence was not 
uncommon with apomorphine but was severe in only one patient, despite the concomitant use 
of oral dopamine agonist treatment by around half of the patients randomised to 
apomorphine. Neuropsychiatric AEs occurred more commonly in the apomorphine arm, but 
  
22 
 
almost all resolved; the only case of impulse control disorder was a mild and short-lasting 
case of hypersexuality which resolved on dose reduction.  
 
From a practical viewpoint, our study shows that some patients tolerate and receive benefit 
from doses exceeding the common range of hourly flow rates currently used. Many centres 
use higher flow rates than the mean dose in our study and it is possible that the full potential 
of apomorphine has not been exploited here. It is also noteworthy that while most patients 
were initiated as inpatients, outpatient initiation was also possible.  
 
TOLEDO was not powered to study an antidyskinetic effect of apomorphine infusion, which 
had been observed in many open-label studies. ‘On’ time without troublesome dyskinesia 
increased significantly but, as in the randomised LCIG study,23 baseline dyskinesia severity 
was relatively low, which may explain the lack of a significant change in existing 
dyskinesias. Dyskinesias were reported as an AE in 14·8% of apomorphine-treated patients; 
however, the majority of these instances (five out of eight patients) were limited to the dose-
adjustment phase where dyskinesias were used as a trigger for oral dose reduction.  
 
The TOLEDO study is an important addition to the evidence-base for apomorphine infusion 
in PD. However, our study had some limitations.  
 
Almost one-third of patients did not complete the full 12-week, double-blind phase. Half of 
these (18 of 36 patients) switched into the open-label phase early. In nearly all cases (17 of 
18) this was due to lack of study drug efficacy, and 16 of these 18 patients were from the 
placebo arm. The rate of patients choosing this option had been expected to be higher in the 
placebo arm, and this can be considered an indirect indicator of superior efficacy of 
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apomorphine. Nevertheless, the uneven rates of discontinuation may have caused a degree of 
bias. In addition, in clinical practice, oral dopamine agonists are often either discontinued 
before starting apomorphine, or gradually reduced and discontinued after starting treatment, 
usually more rapidly than in our study. Here, oral dopamine agonists were reduced slowly or 
in some cases not discontinued completely. Thus, dual agonist treatment may have 
contributed to AEs. Offering patients the option of switching to open-label apomorphine 
infusion was considered necessary for ethical reasons because the study was performed in 
countries where apomorphine is part of standard clinical management.  
 
Although blinding success was not formally assessed, considerable efforts were made to 
maintain blinding throughout the study. However, some inherent features and practical 
aspects of apomorphine infusion therapy (including its rapid and powerful onset of effect,2 
the common requirement to reduce oral medication, and relatively frequent visible changes at 
the needle insertion site) could potentially have influenced blinding. Although patients were 
required to be apomorphine infusion naïve, use of apomorphine injections in the past was 
allowed, to reflect the population who would normally be offered apomorphine infusion. 
While the onset of clinical effect of the infusion is slower than with injections, and although 
the dose was increased gradually, it is conceivable that familiarity with the drug’s effects may 
have occurred. In addition, the MDS-UPDRS was the only outcome measure that was 
directly clinician-assessed and a similar familiarity with the effects of apomorphine may have 
had an impact on blinding  
 
The relatively short study duration may have precluded opportunities for some important 
clinical benefits. In clinical practice the process of adjusting the flow rate of apomorphine 
and oral medication sometimes exceeds 4 weeks. For example, clinicians aim at greater oral 
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dose reductions when dyskinesias are a concern, and maximum dyskinesia reduction may 
take up to several months.24 The relatively short dose-adjustment period and overall study 
duration, as well as the insufficient power of the study, may also explain why a significant 
effect on patient quality of life was not demonstrated in this study, despite the significant 
benefit of apomorphine on PGIC. Such an effect has otherwise been quite consistently shown 
in open-label studies of apomorphine infusion, including in longer-term and multi-centre 
studies.25-27 Shorter-term (12–18-weeks) randomised trials of other efficacious 
antiparkinsonian medications have also failed to detect changes on QoL scales.28,29 The 
results of the 52-week open-label phase will show whether patients randomised to active drug 
went on to improve further once the doses of apomorphine and oral drugs could be adjusted 
individually. 
 
In summary, the TOLEDO study is the first randomised, double-blind, adequately powered 
and well-controlled study in patients with PD to confirm the beneficial clinical effects of 
apomorphine infusion, reported in uncontrolled studies over many years, on motor 
fluctuations that persist despite adjustments in oral/transdermal medication. Continuous 
subcutaneous administration of apomorphine allows the dosage and number of 
administrations of shorter-acting oral PD medication to be reduced. Although no 
comparative, randomised studies versus LCIG exist, both infusion treatments have similar 
effect sizes 28 and apomorphine infusion is easily reversible and less invasive than LCIG, 
which requires the insertion of a gastric tube.  
 
Our study aimed to reflect actual clinical practice, including regional differences, and to 
fairly represent the population of PD patients who are routinely offered this treatment. The 
results provide high-level evidence that apomorphine infusion leads to a pronounced 
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improvement in ‘off’ time, which is associated with an increase in good ‘on’ time and is 
clinically meaningful in the patients’ own view.  
 
The results of the TOLEDO study reflect the positive ‘real world’ effects observed by 
clinicians over many years and support the findings of previous open-label studies. In 
addition to the confirmatory evidence that this RCT now provides for the development of PD 
treatment guidelines, it is hoped that it will also provide practical guidance for clinicians so 
that apomorphine infusion can be offered and reimbursed more widely as an effective 
treatment option. 
 
Research in context  
Evidence before this study 
The long-term management of Parkinson’s disease (PD) is very commonly limited by the 
development of motor complications. In some patients, motor fluctuations are persistent 
despite repeated adjustments of oral (and transdermal) medication, including the use of long-
acting formulations. The dopamine agonist apomorphine, which acts on all dopamine 
receptor subtypes and is administered subcutaneously, has been licensed since 1993 as a 
treatment option for the management of motor fluctuations in patients with PD which cannot 
be sufficiently controlled by oral PD medication. Since that time, it has been used in clinical 
practice in many countries. The efficacy of intermittent apomorphine injection therapy has 
been demonstrated in randomised studies. In contrast, the positive clinical experience with 
apomorphine infusion has been supported by many uncontrolled, open-label studies, but a 
search of PubMed up to February 2014 using the search terms ‘apomorphine’ and ‘infusion’ 
was not able to identify any randomised, double-blind, placebo-controlled clinical trials 
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assessing the efficacy and safety of apomorphine delivered as a continuous infusion in 
patients with PD experiencing persistent motor fluctuations after adjustments in 
oral/transdermal medication. 
Added value of this study 
The TOLEDO Study is the first randomised, double-blind clinical trial to investigate the 
efficacy, safety and tolerability of apomorphine subcutaneous infusion compared with 
placebo in PD patients whose motor fluctuations are uncontrolled despite optimised oral PD 
therapy. It will therefore provide the high-level evidence currently lacking. 
Implications of all the available evidence 
The results of the double-blind phase of the TOLEDO Study provide the first confirmation 
from a large, randomised clinical trial that apomorphine infusion can provide a significant 
and clinically meaningful reduction in ‘off’ time without increasing dyskinesias and is an 
effective treatment strategy for PD patients whose motor fluctuations remain uncontrolled 
despite optimised oral/transdermal therapy. The treatment effect was found to be of the same 
magnitude as that observed in the only other large, randomised study of an infusion therapy 
in PD patients, of intestinal levodopa/carbidopa gel infusion, and exceeds that seen with oral 
or transdermal medication when tested in the setting a placebo-controlled, randomised trial. 
Continuous infusion of apomorphine was well-tolerated in this population, which included 
older PD patients, and also allowed for a significant reduction in the required doses of 
concomitant oral PD medications. Apomorphine infusion has been in widespread clinical use 
for the treatment of motor fluctuations in PD patients in many countries for several decades, 
despite the lack of confirmatory evidence from an RCT. The TOLEDO study now provides 
this evidence and can help inform the development of PD treatment guidelines. Importantly, 
it provides clinicians with guidance on the practical use of apomorphine infusion for the 
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effective management of suitable PD patients in routine clinical practice, which should 
encourage its wider use and reimbursement.  
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Figures and Tables 
Figure 1. TOLEDO study design – 12-week double-blind phase. 
 
COMT, catechol-O-methyl transferase inhibitor; DA, dopamine agonist; ECG electrocardiogram; 
MAO-B, monoamine oxidase-B inhibitor; tid, three times daily. Following completion of a 12-week, 
parallel group, double-blind, placebo-controlled phase, or in case of withdrawal due to lack of 
efficacy, patients could enter a 52-week open-label phase. 
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Figure 2. CONSORT diagram.   
  
Excluded (n=21)* 
• Not meeting inclusion criteria (n=13) 
• Not meeting exclusion criteria (n=8) 
• Other reasons (n=4) 
  *Multiple counts possible 
Randomised (n=107) 
Allocated to apomorphine (n=53) 
• Received allocated intervention (n=53) 
  
Completed double-blind 
phase (n=41) 
Assessed for eligibility (n=128) 
Switched to open-label phase 
(n=2) 
• Lack of efficacy (n=1) 
• Other (n=1) 
Discontinued study 
prematurely (n=10) 
• Adverse event (n=6) 
• Patient’s wish (n=3) 
• Non-compliance (n=1) 
  
Completed double-blind 
phase (n=30) 
Switched to open-label phase 
(n=16) 
• Lack of efficacy (n=16) 
 
Discontinued study 
prematurely (n=8) 
• Patient’s wish (n=4) 
• Non-compliance (n=3) 
• Other (n=1) 
 
Allocated to placebo (n=54) 
• Received allocated intervention (n=53) 
• Did not receive allocated intervention  
(partially treated with apomorphine) (n=1) 
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Figure 3a. Change in the various PD motor states between baseline and Week 12 based 
on home diary results.  
Values are 95% confidence interval for the mean. LOCF, last observation carried forward. P-
value is apomorphine versus placebo using Wilcoxon rank test. 
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Figure 3b. PD motor states at each visit based on home diary results.  
For each variable, data shown are the average from the motor symptom diary for the 2 
consecutive days prior to the visit. Values are 95% confidence interval for the mean. LOCF, 
last observation carried forward. P-value is apomorphine versus placebo using Wilcoxon rank 
test.  
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Figure 4. Patient Global Impression of Change from baseline to Week 12.  
 
P-value is apomorphine versus placebo using Wilcoxon rank test. 
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Figure 5. Change in levodopa-equivalent dose (mg) from baseline to Week 12 (full 
analysis set*).   
Values are 95% confidence interval for the mean. P-value is apomorphine versus placebo 
using Wilcoxon rank test. 
 
  
 
 
*Analysis excludes PRN use and missing data from three sites.  
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Table 1. Baseline characteristics (full analysis set). 
 
 Apomorphine 
(n=53) 
Placebo  
(n=53) 
Total 
(n=106) 
Gender 
Male, n (%) 
Female, n (%)  
 
34 (64·2%) 
19 (35·8%) 
 
32 (60·4%) 
21 (39·6%) 
 
66 (62·3%) 
40 (37·7%) 
Age, mean (SD)  
 
Age group, n (%) 
<65 years 
≥65 years  
63·6 (9·3) 
 
 
26 (49·1) 
27 (50·9) 
63·0 (8·3) 
 
 
29 (54·7%) 
24 (45·3%)  
63·3 (8·8) 
 
 
55 (51·9%) 
51 (48·1%) 
Duration of PD, years 11·8 (5·6) 10·6 (4·3) 11·2 (5·0) 
Daily levodopa dose, mg (mean, SD) 920·4 (518·7) 989·0 (461·4) 954·38 (489·8) 
Daily levodopa-equivalent dose, mg (mean, SD) 1,485·5 (702·6) 1,472·6 (567·9) 1,479·10 (636·2) 
‘Off’ time, mean h/day (SD) 6·69 (2·23) 6·76 (2·51) 6·73 (2·36) 
‘On’ time without troublesome dyskinesia, mean 
h/day (SD) 
 
8·52 (2·36) 8·56 (2·39) 8·54 (2·36) 
MDS-UPDRS Part III during ‘on’ 
 Mean (SD) 
 
 
30·6 (13·65) 
 
28·02 (15·25) 
 
29·34 (14·43) 
PDQ-8 score, mean (SD) 
 
32·67 (15·03) 31·01 (12·66) 31·84 (13·86) 
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Table 2. Summary of efficacy findings at Week 12 (full analysis set). 
  
Change from baseline to Week 12 
Apomorphine 
(n=53) 
Placebo  
(n=53) 
Treatment 
difference  
(95% CI) 
p-value 
Primary endpoint 
  
 
 
Absolute change in time spent ‘Off’ (h/day)  -2·47 -0·58 -1·89 
(-3·16, -0·62) 
0·0025 
Pre-specified secondary endpoints 
    
Number (%) of patients with response to therapy 
(‘off’ time reduction of ≥2 hours)  
33 (62·3%) 15 (28·8%) 33·4%  
(15·48, 51·36) 
0·0008 
Patient Global Impression of Change (mean 
score at Week 12) 
 
3·2 4·4 -1·20  
(-1·71, -0·69) 
<0·0001 
Absolute change in time spent ‘On’ without 
troublesome dyskinesia (h/day) 
 
2·77 0·8 1·97 
(0·69, 3·24) 
0·0008 
Change in oral levodopa dose, mg (mean, SD) 
 
-207·8 (439·5) -94·3 (273·4) -113·5 
(-262·3, 35·2) 
0·0615 
Change in levodopa-equivalent dose, mg (mean, 
SD) 
 
-492·1 (618·3) -163·7 (367·5) -328·5 
(-535·2, -121·7) 
0·0014 
Change in MDS-UPDRS Part III motor scores 
during ‘on’ periods 
 
-3·42 -0·89 -2·52  
(-7·53, 2·48) 
0·4642 
Change in quality of life (PDQ-8) -0·06 2·40 -2·47  
(-7·62, 2·69) 
0·3971 
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Table 3. Summary of adverse events (AE) by Week 12 (safety set). 
 
  Values are n (%) 
Apomorphine 
(n=54) 
Placebo  
(n=53) 
At least one treatment-emergent AE (TEAE) 50 (92·6%) 30 (56·6%) 
Most common TEAE (≥10% of patients)   
Skin nodules at infusion site 
Mild 
Moderate 
 
24 (44·4%) 
20 (37·0%) 
4 (7·4%) 
 
0 
0 
0 
Nausea 
Mild 
Moderate 
12 (22·2%)  
10 (18·5%) 
2 (3·7%) 
      
5 (9·4%)  
3 (5·7%) 
2 (3·8%)      
 
Somnolence 
Mild 
Moderate 
Severe 
 
12 (22·2%) 
5 (9·3%)   
6 (11·1%)   
1 (1·9%) 
      
2 (3·8%) 
1 (1·9%) 
1 (1·9%) 
0 
Infusion site erythema 
Mild 
Moderate 
 
9 (16·7%) 
8 (14·8%) 
1 (1·9%) 
 
2 (3·8%)  
2 (3·8%)     
0    
 
Dyskinesia 
Mild 
Moderate 
 
8 (14·8%) 
5 (9·3%) 
3 (5·6%) 
0 
0 
0 
Headache 
Mild 
Moderate 
 
7 (13·0%)    
6 (11·1%)   
1 (1·9%) 
 
2 (3·8%)  
2 (3·8%)  
0 
Insomnia 
Mild 
Moderate 
 
6 (11·1%) 
2 (3·7%) 
4 (7·4%) 
1 (1·9%) 
0 
1 (1·9%) 
 
At least one AE with a local intolerability  
(skin changes at injection site) 
 
32 (59·3%) 
 
8 (15·1%) 
 
Severe AES 8 (14·8%) 2 (3·8%) 
Serious AEs 5 (9·3%) 2 (3·8%) 
AEs leading to study discontinuation 6 (11·1%) 0 
AEs leading to dose modification 26 (48·1%) 6 (11·3%) 
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Supplementary material 
 
Figure S1. Subgroup analysis: change from baseline in absolute time spent 'off' by 
gender and age group.  
Values are mean (95% confidence intervals [CI]). FAS, full analysis set; last observation 
carried forward). P-value for the primary analysis is apomorphine versus placebo using 
Wilcoxon rank test. P-values for subgroups are for the interaction term between the subgroup 
and treatment. 
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Figure S2. Sensitivity analysis Forest plot for change in ‘off’ time at Week 12.  
Values are mean (95% confidence intervals [CI]). FAS, full analysis set; LOCF, last 
observation carried forward; LCL, lower confidence limit; UCL, upper confidence limit; 
MMRM, mixed models for repeated measure; MI, multiple imputation.  
 
  
MMRM  Model includes treatment, visit, treatment*visit interaction and baseline ‘off’ time  
Protocol defined MI Multiple imputation (MI) of missing ‘off’ times using treatment and baseline ‘off’ time 
using Monte-Carlo Markov-Chain method with non-informative prior distribution 
Post-titration LOCF Last observation carried forward (LOCF) using only post-titration visits  
MI accounting for 
treatment  
MI of ‘off’ time change from baseline assuming monotone missing data using 
regression model containing treatment, baseline ‘off’ time and observed/imputed 
‘off’ times at previous visits  
MI ignoring treatment As ‘MI accounting for treatment’ excluding treatment from the model 
MI placebo only As ‘MI accounting for treatment’ with apomorphine patients assumed to receive 
placebo after premature discontinuation  
  
  
39 
 
Table S1. Breakdown of patients by country according to treatment group (full analysis 
set). 
  
Apomorphine  
(n=53) 
Placebo  
(n=53) 
Total 
(n=106) 
Country (n of centres), n (%) 
Austria (3) 
Denmark (1) 
France (3) 
Germany (4) 
Netherlands (3) 
Spain (5) 
United Kingdom (4) 
 
7 (13.0%) 
1 (1.9%) 
7 (13.0%) 
10 (18.5%) 
7 (13.0%) 
12 (22.2%) 
9 (16.7%) 
 
5 (9.3%) 
2 (3.7%) 
4 (7.4%) 
10 (18.5%) 
7 (13.0%) 
14 (25.9%) 
11 (20.4%) 
 
12 (11.2%) 
3. (2.8%) 
11 (10.3%) 
20 (18.7%) 
14 (13.1%) 
26 (24.3%) 
20 (18.7%) 
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Table S2. Anti-PD medications at baseline and Week 12.  
 
 Apomorphine  Placebo 
Anti-PD drug category Baseline 
(n=54) 
Week 12 
(n=54) 
Baseline 
(n=53) 
Week 12 
(n=53) 
Levodopa-containing drug 54 53 53 53 
Dopamine agonist 48 28 43 38 
MOA-B inhibitor 23 19 21 21 
Amantadine 16 13 13 13 
Total* 141 113 130 125 
 
*Patients can be in more than one row. Includes patients who discontinued the double-blind phase early; these 
had their last visit assigned to Week 12. 
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Table S3. Summary of efficacy findings at Week 12 (full analysis set) – post hoc 
analyses. 
 
Change from baseline to Week 12 Apomorphine 
(n=53) 
Placebo  
(n=53) 
Treatment 
difference  
(95% CI) 
p-value 
Absolute change in time spent ‘On’ without 
dyskinesia (h/day) 
 
3·06 1·09 -1·97 
(0·67, 3·27) 
0·0018 
Absolute change in time spent ‘On’ with non-
troublesome dyskinesia (h/day) 
 
-0·29 -0·29 -0·00 
(-1·02, 1·01) 
0·6066 
Absolute change in time spent ‘On’ with 
troublesome dyskinesia (h/day) 
 
-0·24 -0·09 -0·15  
(-0·79, 0·48) 
0·4682 
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Table S4. Frequency of patients experiencing ‘on’ time with troublesome dyskinesia at 
baseline (full analysis set). 
 
On with troublesome 
dyskinesia at baseline 
(hours) 
Frequency 
(FAS)  
Cumulative 
Frequency 
0 54 54 
0.25 3 57 
0.5 4 61 
0.75 5 66 
1 4 70 
1.25 3 73 
1.5 3 76 
1.75 4 80 
2 2 82 
2.25 1 83 
2.5 3 86 
2.75 3 89 
3 4 93 
3.25 4 97 
3.5 3 100 
4.5 1 101 
4.75 1 102 
5.5 2 104 
5.75 1 105 
6.75 1 106 
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Table S5. Mean levodopa-equivalent dose at baseline and Week 12 by drug category 
(safety set). 
 
     Levodopa-equivalent dose (mg) mean (SD) 
  Apomorphine Placebo 
Anti-PD drug category 
Baseline  
(n=54) 
Week 12  
(n=54) 
Baseline  
(n=53) 
Week 12  
(n=53) 
Levodopa-containing drug 1055.1 (656.03) 812.5 (419.24) 1105.7 (543.76) 993.8 (417.51) 
Dopamine agonist 347.4 (277.13) 203.6 (151.69) 277.9 (137.72) 247.8 (119.78) 
MOA-B inhibitor 94.0 (20.60) 97.4 (11.47) 97.6 (10.91) 97.6 (10.91) 
Amantadine 200.0 (81.65) 200.0 (91.29) 250.0 (95.74) 250.0 (95.74) 
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Table S6. Summary of exploratory efficacy and safety endpoints evaluated in the study. 
Efficacy endpoints 
• Change in Score of the Non-Motor Symptoms Scale for PD 
• Change in MDS-UPDRS Part I patient questionnaire (non-motor experiences of daily 
living) 
• Change in MDS-UPDRS II, assessed separately for ‘on’ and ‘off’ states 
• Change in MDS-UPDRS Part IV fluctuations  
• Drop-outs due to lack of efficacy 
• Beck Depression Scale 
• PDSS (PD Sleep Scale) 
 
Safety endpoints: 
• Evaluation of adverse events and local tolerability 
• Skin changes 
• Full blood count 
• Epworth Sleepiness Scale 
• QUIP 
• C-SSRS (Columbia-Suicide Severity Rating Scale) 
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Table S7. Summary of adverse events (AE) at Week 12 (safety set) showing Clopper–Pearson exact confidence intervals (%). 
 
  Values are n (%) 
Apomorphine Placebo 
(n=54) (n=53) 
At least one treatment-emergent AE (TEAE) 50 (92·6%) (82·11–97·94) 30 (56·6%) (42·28–70·16) 
  
  
Most common TEAE (≥10% of patients)  
  
Skin nodules at infusion site 24 (44·4%) (30.92–58.6) 0 (0–5.50) 
 Mild 20 (37·0%) (24.29–51.26) 0 (0 –5.50) 
 Moderate 4 (7·4%) (2.06–17.89) 0 (0–5.50) 
  
  
Nausea 12 (22·2%) (12.04–35.6) 5 (9·4%) (3.13–20.66) 
 Mild 10 (18·5%) (9.25–31.43) 3 (5·7%) (1.18–15.66) 
 Moderate 2 (3·7%) (0.45–12.75) 2 (3·8%) (0.46–12.98) 
  
  
Somnolence 12 (22·2%) (12.04–35.6) 2 (3·8%) (0.46–12.98) 
 Mild 5 (9·3%) (3.08–20.3) 1 (1·9%) (0.05–10.07) 
 Moderate 6 (11·1%) (4.19–22.63) 1 (1·9%) (0.05–10.07) 
 Severe 1 (1·9%) (0.05–9.89) 0 (0–5.50) 
  
  
Infusion site erythema 9 (16·7%) (7.92–29.29) 2 (3·8%) (0.46–12.98) 
 Mild 8 (14·8%) (6.62–27.12) 2 (3·8%) (0.46–12.98) 
 Moderate 1 (1·9%) (0.05–9.89) 0 (0–5.50) 
  
  
Dyskinesia 8 (14·8%) (6.62–27.12) 0 (0–5.50) 
 Mild 5 (9·3%) (3.08–20.3) 0 (0–5.50) 
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 Moderate 3 (5·6%) (1.16–15.39) 0 (0–5.50) 
  
  
Headache 7 (13·0%) (5.37–24.9) 2 (3·8%) (0.46–12.98) 
 Mild 6 (11·1%) (4.19–22.63) 2 (3·8%) (0.46–12.98) 
 Moderate 1 (1·9%) (0.05–9.89) 0 (0–5.50) 
  
  
Insomnia 6 (11·1%) (4.19–22.63) 1 (1·9%) (0.05–10.07) 
 Mild 2 (3·7%) (0.45–12.75) 0 (0–5.50) 
 Moderate 4 (7·4%) (2.06–17.89) 1 (1·9%) (0.05–10.07) 
  
  
At least one AE with a local intolerability (skin 
changes at injection site) 
32 (59·3%) (45.03–72.43) 8 (15·1%) (6.75–27.59) 
   
Severe AES 8 (14·8%) (6.62–27.12) 2 (3·8%) (0.46–12.98) 
  
  
Serious AEs 5 (9·3%) (3.08–20.3) 2 (3·8%) (0.46–12.98) 
   
AEs leading to study discontinuation 6 (11·1%) (4.19–22.63) 0 (0–5.50) 
  
  
AEs leading to dose modification 26 (48·1%) (34.34–62.16) 6 (11·3%) (4.27–23.03) 
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